Listing 1 - 3 of 3 |
Sort by
|
Choose an application
Objective: Cervical cancer is the fourth most common cancer worldwide. Several risk factors have been identified to influence overall survival (OS) and progression free survival (PFS). There is a high risk for recurrence of cervical cancer if patients have positive lymph nodes, parametrial or vaginal wall invasion. Therefore, adjuvant radiotherapy is advised in such circumstances. Predictors for intermediate risk for recurrence are lymphovascular invasion (LVI), deep stromal invasion and large tumor size. Unfortunately, it is still not clear whether these patients should receive adjuvant therapy or not. Method: All patients with cervical cancer FIGO stage IB1 were included into the study over a 20-year period. All information concerning patient and tumor characteristics, follow-up and recurrence was gathered. Primary aim of the study was to analyze the recurrence rate. Secondary aim was to identify the risk factors important for disease recurrence. Results: Two hundred-and-one patients were included into the study, of which 23 (11%) had disease recurrence. Pelvic lymphadenectomy (HR=0.0445; P=0.0002) and the location of recurrence (P=0.0059) were the only risk factors influencing OS. Intermediate risk factors did not influence OS or PFS. Event number was too low to extrapolate data out of the risk models. Conclusion: Recurrence rate was rather low (11%). The performance of a pelvic lymphadenectomy and the location of recurrence were the sole risk factors influencing survival. Intermediate risk factors do not affect OS or PFS. In contrast to previous reports, large tumor size in patients with stage IB1 has no effect on prognosis.
Choose an application
Introduction: Lymphovascular space invasion (LVSI), deep (>1/3) stromal invasion (DSI) and large tumor size (> 4 cm) have been identified as predictors for intermediate risk for recurrence according to Sedlis (at least two of the prior risk factors) in FIGO stage I cervical cancer. Adjuvant radiotherapy (RT) has been advocated in these patients, but remains controversial. Method: All consecutive patients (1997-2017) with cervical cancer FIGO (2009) stage IB1 (≤4 cm) were included. Primary aim was to analyze the recurrence rate. Secondary aim was to identify the risk factors for disease recurrence and survival. Results: One-hundred-and-eighty-two patients were included in this retrospective study. Median follow-up was 13 years (range 8-17). Postoperatively, 21 patients received adjuvant therapy due to presence of positive lymph nodes, positive section margins or if a simple hysterectomy was performed (RT: n=7, concomitant chemo radiotherapy (CCRT): n=14). None of the patients with a combination of intermediate risk factors according to Sedlis (excluding patients > 4 cm) underwent adjuvant RT/CCRT. Disease recurrence was observed in 19 patients (10%). Eleven patients died of disease. LVSI influenced progression-free survival (PFS) (HR 3.950, p=0.0163) and disease-specific survival (DSS) (HR 4.637, p=0.0497) significantly. However, the combination of LVSI, tumor size and DSI according to Sedlis did not influence overall survival (OS), DSS or PFS. Conclusion: Recurrence rate was low (10%), despite the fact that patients with intermediate risk factors according to Sedlis did not receive postoperative RT/CCRT. LVSI was the sole risk factor influencing PFS and DSS. Combinations of risk factors according to Sedlis did not predict worse outcome.
Choose an application
Listing 1 - 3 of 3 |
Sort by
|